RXFILES

RxFiles - Drug Comparison Charts
11th Edition (March 2017)

CHART PEARLS 11th Edition

By the Numbers
Changes: thousands. Charts updated daily, then to web/apps.

Colors and Symbols
See pg 202 (back cover) for the RxFiles risk categories.

$ Comparisons that caught our
Generics unavailable for awhile:
Clomipramine ANAFRANIL, Nortriptyline AVENTYL

Hepatitis C Treatment Regimens $/longest cycle
Harvoni  $71 K
Holkira Pak  $112 K
Zepatier  $60 K

Substantially REDUCED Cost
(Also new g: Adderal XR, Avelox, Detrol LA, Fosavance, Inflectra, Tecta & Vesicare)
Levetiracetam g = KEPPRA  500mg BID $225→$120/100d
Quetiapine g = SEROQUEL 300mg BID $99→$56/30d
Isotretinoin g = ACCUTANE, CLARUS, EPIRUS $100,420, 457, 570/course
Doxycycline g = VIBRA-TABS 100mg OD $47→$28/4wk
Zolpidem SUBLINQ 5mg HS $56→$20/30d

Status & Reimbursement Changes

• On SK Formulary: ANDROCUR, carvedilol, CLAVULIN, CLOPIXOL, colesvelem susp, COMBIVENT RESPIMAT, escalopram, gabapentin 600 &
  800mg tabs, JAYDESS, midodrine, minocycline, PLAN B, & SIMBRINZA.

• New EDS ³: ABILIFY MAINTENA, AECTMRA SC, FIBRISTAL, ANORO &
  BREO ELLIPTA, APTIOM, DIOXIMET, DICIFID, DIFLUKIR GENUAI, ELSIQUIS,
  HARVONI, HOKIRI PAK, INCLUSA ELLIPTA, INFLAXA, INSPILOTO
  RESPIMAT, INSPRRA, INVOKANA, JARDIANE, KOMBOLGY, LALUTA,
  MYRBTREX, ONCENA SC, PLAVIX, PREVICID FASTAB, PREZOBIX,
  SPIRVA RESPIMAT, SOVALDI, TIVICAY, TRIUMEQ, ULIBRO BREEZHALER,
  VYVANSE 10MG & XELIANZ.

• New generics³: AZILECT, BEZALIP SR, cefixime, cلهoxiel, CLINDOXYL,
  duloxetine, KIVEXA, NASACORT, OMINARIS, SUBOXONE, TAMIFLU,
  VALCYTE, zolpidem

• New full NIH³: AGGRANOX, alendronate, ALPHAPAN P, BUSPAR,
  cipro susp, CLIMARA PRO, CLINDOXYL, CLOPIXOL, COMBIVENT
  RESPIMAT, CYTOMET, DETROL LA, DIVIGEL, EDARBI, EZETROL, FELECIT,
  FIBRISTAL, FOSAVANCE, isosorbide mononitrate, JAYDESS, KEPPRA, LOLO,
  MONA LIISA IJD, moexfloxacin, PLAN B, PREGCOBIX, risendronate,
  TIVICAY, VESICARE, VIGAMOX, VIRAMUNE XR & ZYMAR.

• New prior NIH approval ³: ABILIFY MAINTENA; ANORO, BREO &
  INCREASE ELLIPTA; APTIOM, COSENTYX, DIATAXT, DUALKIR, fosfomycin,
  FOSFOMI, GALEXOS, HARVONI, INSPRRA & SPIRVA RESPIMAT,
  INFLAXA, INVOKANA, JARDIANE, KADIAN, KOMBOLGY, LALUTA,
  Levetiracetam, PENNSAID, SOVALDI, TOVIAZ, TURDORZA, ULIBRO
  BREEZHALER, Vit E & XELIANZ.

• New OTC: ADVIL 12HR, FLONASE, OLEX & NEXIUM

Outcome Evidence from MAJ OR Trials

Major outcome trials & drug dosages used are often noted on charts when pertinent. Relative recently: EMPA-REG (Empagliflozin and
CV outcomes), FLAME (Ultibro Breezhaler vs Advair in COPD), IMPROVE-IT (ezetimibe +
simvastatin vs simvastatin), LEADER (Liraglutide vs Placebo in T2DM), PARADIGM-HF
(valsalta + sacubitril vs enalapril), PEGASUS-TIMI (Ticagrelor vs Placebo in patients with he
of MI), PIONEER AF-PCI (Rivaroxaban in A Fib), PRECISION (Celecoxib, Ibuprofen or
naproxen in osteoarthritis/RA), SOCRATES (Ticagrelor in stroke/ TIA vs ASA ), SPRINT (is
120mmHg the new 140mmHg) & SUMMIT (Breeo ellipta vs Relvar in COPD + CV patients).

Scanning Through The Charts

• Hypertension – SPRINT trial summary pg 11-12
• AFB – added new guidelines (CCS’16,ESC’16), edoxaban pg 22
• Thyroid Disorders – enhanced treatment information pg 55-56
• H. Pylori Testing & Eradication – new regimens, length of
  therapy & how to verify elimination pg 69
• Irritable Bowel – new medications (rifaximin, linclotide) pg 70
• CAP – added SOAR guidelines pg 93-94
• Contraceptives – new brands, MIFEGRMISO pg 129-130
• Peri-Pregnancy – new guidelines and folic acid info pg 135-136
• Bipolar Chart – definitions, introduction, overview pg 147-148
• COPD and Asthma – new devices, more in-depth info on
  goals of tx, risk factors, diagnosis & triggers for each condition pg 159-163
• Cannabinoids – regulation changes pg 167

New Charts - 7 in all

• Angina Pg 3-4
• DAPT & Triple Therapy Pg 19-20
• Bipolar in Pregnancy Pg 149-150
• Asthma Overview & Drug Chart Pg 159-160
• COPD Overview & Drug Chart Pg 161-162
• Drug Interactions Pg 175-178
• Alcohol Use Disorders Pg 185-186

New Drug (Brand Name) Additions

ADDY1, ARNOTY ELIPTA, BASAIALT INSULIN, BRENZYS, BYDUREON,
DAKUNZA, DOXOBET, DUXLAR, DYMSTA, ELLA, ENRESTO, ENTYMO,
EPLUSLA, FETZIMA, FORXO, GARASIL, GENVOYA, HOLKIRA,
INSPILOTO, INVOKAMET, KAZANO, LANCOPA, LIXANA, LUNESTA,
MOVANTIF, MIFEGYMISO, NATESTO, NESINA, NACLAL, PLEGIDRY,
PRALUENT, PRAXBIND, REPATHA, SAVAYAS, SIMBIRNA, SPIRIVA
RESPIMAT, SYNJARDY, PRALUENT, TRIUMEQ, TRICITY, VIBATIX, XEDROJ,
ZERBAXA & ZINERYT...

Highlights of Just a Few of the Revisions

Guidelines Reviewed & Incorporated into Charts
ACC’16 Role of Non-Statin tx in CVD Risk, ACIP’17 USA Adult &
Pediatric Vaccine, ACR’15 Rheumatoid Arthritis, ADA’17 Diabetes
Update, AGS’15 Beers Update, CANMAT’16 Major Depressive
Disorder, CCS’16 Dyslipidemia for CVD prevention, CDN’15 Acne,
CHEP’16 Hypertension, CTS’15 Asthma in Preschoolers, SOGC’15
Contraception, SOGC’15 Vulvovaginitis, USPSTF’16 ASA Primary
Prevention CVD/Cancer etc

Antiplalet and Antithrombotic

Pg 17-20
• New trials: TRITON-TIMI 38, TRILOGY, PLATO, PEGASUS and DAPT
• DAPT Recommendations and Chart
• DOAC reversal with PRAXBIND

Diabetes

Pg 39-51
• New CV trials added, new drugs, updated SMBG meters

Hepatitis C

Pg 87-88
• New drugs and new treatments regimens in special populations

HIV chart

Pg 89-90
• Added new drug combos and new 2016 international guideline
  recommendations

Chronic Non-Cancer Pain Chart

Pg 99
• Updated neuropathic pain treatment regimens from national and
  international guidelines & updates from 2017 CND Opioid Guidelines

RxFiles Academic Detailing  c/o Saskatoon City Hospital, 701 Queen Street, Saskatoon, SK Canada  S7K 0M7
TEL: (306) 655-8505  FAX: (306) 655-7980  Email: via our website.  www.RxFiles.ca
Recent Adverse Reaction Advisories

- ABILIFY products linked with impulsive behaviours like pathological gambling and hypersexuality
- Celecoxib >200mg/d is linked with serious CV adverse effects similar to diclofenac >150mg/d and ibuprofen >2400mg/d
- Domperidone linked with ventricular arrhythmias and sudden cardiac death
- FORXIGA AND INVOKANA linked to acute kidney injury
- Febuxostat: HF risk warning in patients with pre-existing CV disease
- Fluoroquinolones: associated with retinal detachment & Tendonitis, Achilles tendon rupture & nerve damage
- Metoclopramide: EPS risk in children on therapeutic doses (CI in children <1yr old)
- TEICIFERDA (dimethyl fumarate) linked with risk of PML

Pictures & Colors Speak 1000 Words

COLOURS USED WITHIN THE CHARTS
- Green shading usually indicates HERBAL/LIFESTYLE related
- Blue shading usually indicates PEDIATRIC related
- Dark Blue shading usually indicates ADOLESCENT related
- Tan shading usually indicates ELDERLY related
- Purple script usually indicates TRADE NAMES
- Yellow highlights CLINICAL DIFFERENCES, PRACTICE GAPS & COMMON ??s
- Blue script usually indicates MAJOR TRIALS
- Pink script usually indicates PREGNANCY & LACTATION related
- Red shading usually indicates official FDA black box or HC warning
- Gray script usually indicates DISCONTINUED drug
- Purple shading usually indicates OVERVIEW/GUIDELINE approach

Your notes...

COMMONLY USED ABBREVIATIONS
- AE = Adverse event
- BID = Twice daily
- BP = Blood pressure
- Bz = Benzodiazepine
- CI = Contraindication
- CV = Cardiovascular
- DI = Drug interaction
- Dx = Diagnosis/disease
- HSR = Hypersensitivity reaction
- LFT = Liver function tests
- M = Monitoring
- OTC = Over the counter
- p = Porphyria
- QID = Four times daily
- eGFR = Estimated glomerular filtration rate
- g = Generic available
- GI = Gastrointestinal
- HA = Headache
- HF = Heart failure
- HR = Heart rate
- HS = Bedtime
- SCr = Serum creatinine
- SJS = Stevens Johnson Syndrome
- Sx = Syndrome/symptom
- Sz = Seizure
- TID = Three times daily
- Tx = Treatment/Therapy

DRUGS IN PREGNANCY & LACTATION RISK CATEGORIES

<table>
<thead>
<tr>
<th>PREGNANCY [P]</th>
<th>LACTATION [L]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safe [P]</td>
<td>Safe [L]</td>
</tr>
<tr>
<td>Likely Safe [P]</td>
<td>Likely Safe [L]</td>
</tr>
<tr>
<td>Caution [P]</td>
<td>Caution [L]</td>
</tr>
<tr>
<td>Contraindicated [P]</td>
<td>Contraindicated [L]</td>
</tr>
</tbody>
</table>

- Safe: Compatible in pregnancy
- Likely Safe: No (limited) human data – probably compatible
- Caution: Human, and or animal, data suggest risk
- Contraindicated: Though data are insufficient, drug should be avoided

You’ll see in the charts:
- [P] = pregnancy
- [L] = lactation risk category
- [x] = unknown

What will you see?
- [P] = pregnancy
- [L] = lactation
- [x] = unknown

Unknown for Pregnancy [P] and/or Lactation [L]

- No (limited) human data – no relevant animal data